Entecavir Plus Adefovir in Lamivudine-Resistant Patients
Status:
Withdrawn
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Combination therapy with entecavir 1.0 mg plus adefovir 10 mg has superior antiviral activity
compared with either entecavir monotherapy 1.0 mg or adefovir 10 mg plus lamivudine 100 mg in
Chinese adults with lamivudine-resistant chronic hepatitis B infection